CD163 and neoplasm: A total of 335 patients who had undergone surgery for stage I–IIIA NSCLC were enrolled into this analysis and assessed for CD66b(+) neutrophils and CD163(+) macrophages in tumor nests and the adjacent stroma by means of immunohistochemistry.